

**PB 8 of 2025**

National Health (Listed Drugs on F1 or F2) Amendment Determination (No. 1) 2025

I, Rebecca Richardson, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make the following determination.

Dated 30 January 2025

**REBECCA RICHARDSON**

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health and Aged Care

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments 2

National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021) 2

1 Name

(1) This instrument is the *National Health (Listed Drugs on F1 or F2) Amendment Determination (No. 1) 2025.*

(2)This instrument may also be cited as PB 8 of 2025.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information | | |
| --- | --- | --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | 1 February 2025. |  |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 85AB(1) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021)

1. **Schedule 1, after item dealing with Alemtuzumab**

Omit:

Alirocumab

1. **Schedule 1, after item dealing with Dapagliflozin**

Omit:

Dapsone

1. **Schedule 1, after item dealing with Glucose and ketone indicator urine**

Omit:

Glucose indicator—urine

1. **Schedule 1, after item dealing with Mannitol**

Omit:

Maraviroc

1. **Schedule 1, after item dealing with Ozanimod**

Omit:

Paclitaxel, nanoparticle albumin‑bound

1. **Schedule 1, after item dealing with Selinexor**

Insert:

Selpercatinib

1. **Schedule 1, after item dealing with Tiagabine**

Omit:

Ticagrelor

1. **Schedule 2, after item dealing with Dabigatran etexilate**

Insert:

Dapsone

1. **Schedule 2, after item dealing with Macrogol 3350**

Insert:

Maraviroc

1. **Schedule 2, after item dealing with Paclitaxel**

Insert:

Paclitaxel, nanoparticle albumin‑bound

1. **Schedule 2, after item dealing with Tetrabenazine**

Insert:

Ticagrelor